SCHEMBL16184708

SCHEMBL16184708

COc1cc(-c2cccc(F)c2)cc2c(N3CCCC3C(F)(F)F)nc(-c3cccnc3)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ GBA1 P04062 5/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ PDE2A O00408 5/20 0.36
▸ PDE10A Q9Y233 5/20 0.36
▸ PDE5A O76074 4/20 0.36
▸ PDE11A Q9HCR9 4/20 0.36
▸ PIK3CD O00329 1/20 0.35
▸ PIK3R1 P27986 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ HCRTR1 O43613 2/20 0.34
▸ HCRTR2 O43614 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184790 0.95 MAPT (0.39) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184722 0.93 MAPT (0.38) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184806 0.91 MAPT (0.37) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184756 0.90 MAPT (0.37) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184771 0.90 MAPT (0.37) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184740 0.88 MAPT (0.37) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184691 0.88 MAPT (0.39) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184710 0.86 GBA1 (0.43) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184711 0.84 GBA1 (0.41) MAPTALDH1A1GAAGBA1KDM4E
SCHEMBL16184706 0.84 ALDH1A1 (0.49) MAPTALDH1A1GAAGBA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885ALDH1A1 1687/4885GAA 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback